undamentalytics Newsletter

Nunnelly John N: insider trades

Director at NRC Health. No open-market purchases and 17 sales not made under a pre-set plan, reported from November 15, 2013 to April 4, 2018.

What happened after Nunnelly John N’s sales?

After their sales, the shares moved +13.4% against the index over 12 months on average (a negative figure means selling was the right call); 24% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Nunnelly John N: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 17 +21.3% +26.6% 18% 4 0.59 0.60 No reliable evidence
Sales, 12 months after the report 17 +13.4% +25.1% 24% 4 −0.04 0.97 No reliable evidence
Sales, 12 months after the trade 17 +13.6% +24.5% 24% 4 −0.09 0.93 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
NRC Health NRC —017November 15, 2013April 4, 2018

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
April 4, 2018April 2, 2018 NRC Sale $86,250 +19.0%+21.6%+27.6%
March 29, 2018March 28, 2018 NRC Sale $117,443 +26.2%+27.6%+26.3%
March 28, 2018March 26, 2018 NRC Sale $143,043 +26.6%+25.4%+32.2%
March 26, 2018March 22, 2018 NRC Sale $10,732 +26.9%+28.6%+22.3%
March 22, 2018March 20, 2018 NRC Sale $174,717 +24.8%+29.2%+24.3%
March 20, 2018March 16, 2018 NRC Sale $75,636 +20.8%+21.3%+24.5%
July 5, 2017June 30, 2017 NRC Sale $75,438 +33.8%+24.8%+28.6%
June 30, 2017June 29, 2017 NRC Sale $22,842 +37.0%+28.0%+26.1%
June 29, 2017June 27, 2017 NRC Sale $137,249 +36.1%+28.6%+26.5%
June 27, 2017June 23, 2017 NRC Sale $261,927 +35.7%+27.4%+28.1%
June 22, 2017June 20, 2017 NRC Sale $59,113 +35.6%+28.1%+27.1%
June 20, 2017June 16, 2017 NRC Sale $307,381 +34.5%+23.4%+22.2%
June 16, 2017June 14, 2017 NRC Sale $129,807 +34.9%+25.1%+18.8%
March 17, 2014March 13, 2014 NRC Sale $811,929 −25.9%−26.1%−34.6%
December 5, 2013December 3, 2013 NRC Sale $639,306 +3.6%−30.2%−40.0%
November 19, 2013November 18, 2013 NRC Sale $341,532 −4.5%−33.9%−21.8%
November 15, 2013November 13, 2013 NRC Sale $60,705 −3.5%−21.8%−7.2%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Nunnelly John N traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.